The NCT03196830 phase II trial assessed the role of a DAC-based lymphodepletion regimen preceding CD19 x CD22 TanCAR-T cell infusion in patients with R/R diffuse large B-cell lymphoma (DLBCL). This evidence concerns the gene CD22 and diffuse large B-cell lymphoma.